Meyer WK, Jamison J, Richter R, Woods SE, Partha R, Kowalczyk A, Kronk C, Chikina M, Bonde RK, Crocker DE, Gaspard J, Lanyon JM, Marsillach J, Furlong CE, Clark NL (2018) <br />Ancient convergent losses of Paraoxonase 1 yield potential risks for modern marine mammals<br /><i>Science</i> <b>361</b>: 591<br /><br />Furlong CE, Marsillach J, Jarvik GP, Costa LG (2016) <br />Paraoxonases-1, -2 and -3: What are their functions?<br /><i>Chemico-Biological Interactions</i> <b>259</b>: 51<br /><br />Garrick JM, Dao K, de Laat R, Elsworth J, Cole TB, Marsillach J, Furlong CE, Costa LG (2016) <br />Developmental expression of paraoxonase 2<br /><i>Chemico-Biological Interactions</i> <b>259</b>: 168<br /><br />Souza-Nogueira A, Camargo AE, Remondi FA, Paoliello MM, Richter RJ, Furlong CE, Barbosa DS, Maes M, Moreira EG (2016) <br />Paraoxonase 1 (PON1) Q192R genotypes and their interaction with smoking strongly increase atherogenicity and the Framingham risk score<br /><i>Arch Endocrinol Metab</i> <b>60</b>: 426<br /><br />Cole TB, Li WF, Co AL, Hay AM, MacDonald JW, Bammler TK, Farin FM, Costa LG, Furlong CE (2014) <br />Repeated Gestational Exposure of Mice to Chlorpyrifos Oxon Is Associated with Paraoxonase 1 (PON1) Modulated Effects in Maternal and Fetal Tissues<br /><i>Toxicol Sci</i> <b>141</b>: 409<br /><br />Costa LG, de Laat R, Dao K, Pellacani C, Cole TB, Furlong CE (2014) <br />Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection<br /><i>Neurotoxicology</i> <b>43</b>: 3<br /><br />Kim DS, Crosslin DR, Auer PL, Suzuki SM, Marsillach J, Burt AA, Gordon AS, Meschia JF, Nalls MA, Worrall BB, Longstreth WT, Jr., Gottesman RF, Furlong CE, Peters U, Rich SS, Nickerson DA, Jarvik GP (2014) <br />Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project<br /><i>J Lipid Res</i> <b>55</b>: 1173<br /><br />Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, Maccoss MJ, Hsieh EJ, Rettie AE, Furlong CE (2014) <br />Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase<br /><i>PLoS ONE</i> <b>9</b>: e110054<br /><br />Baker PE, Cole TB, Cartwright M, Suzuki SM, Thummel KE, Lin YS, Co AL, Rettie AE, Kim JH, Furlong CE (2013) <br />Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants<br /><i>Chemico-Biological Interactions</i> <b>203</b>: 257<br /><br />Chen W, Kim JH, Zhang D, Lee KH, Cangelosi GA, Soelberg SD, Furlong CE, Chung JH, Shen AQ (2013) <br />Microfluidic one-step synthesis of alginate microspheres immobilized with antibodies<br /><i>J R Soc Interface</i> <b>10</b>: 20130566<br /><br />Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE (2013) <br />Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity<br /><i>Toxicology</i> <b>307</b>: 115<br /><br />Costa LG, Tait L, de Laat R, Dao K, Giordano G, Pellacani C, Cole TB, Furlong CE (2013) <br />Modulation of Paraoxonase 2 (PON2) in Mouse Brain by the Polyphenol Quercetin: A Mechanism of Neuroprotection?<br /><i>Neurochem Res</i> <b>38</b>: 1809<br /><br />Giordano G, Tait L, Furlong CE, Cole TB, Kavanagh TJ, Costa LG (2013) <br />Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression<br /><i>Free Radic Biol Med</i> <b>58</b>: 98<br /><br />Kim DS, Burt AA, Crosslin DR, Robertson PD, Ranchalis JE, Boyko EJ, Nickerson DA, Furlong CE, Jarvik GP (2013) <br />Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL<br /><i>J Lipid Res</i> <b>54</b>: 552<br /><br />Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, Furlong CE, Jarvik GP (2013) <br />Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol<br /><i>J Lipid Res</i> <b>54</b>: 1512<br /><br />Kim DS, Maden SK, Burt AA, Ranchalis JE, Furlong CE, Jarvik GP (2013) <br />Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects<br /><i>Lipids Health Dis</i> <b>12</b>: 183<br /><br />Kim DS, Marsillach J, Furlong CE, Jarvik GP (2013) <br />Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease<br /><i>Pharmacogenomics</i> <b>14</b>: 1495<br /><br />Marsillach J, Hsieh EJ, Richter RJ, Maccoss MJ, Furlong CE (2013) <br />Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures<br /><i>Chemico-Biological Interactions</i> <b>203</b>: 85<br /><br />Marsillach J, Costa LG, Furlong CE (2013) <br />Protein adducts as biomarkers of exposure to organophosphorus compounds<br /><i>Toxicology</i> <b>307</b>: 46<br /><br />Cole TB, Fisher JC, Burbacher TM, Costa LG, Furlong CE (2012) <br />Neurobehavioral assessment of mice following repeated postnatal exposure to chlorpyrifos-oxon<br /><i>Neurotoxicology & Teratology</i> <b>34</b>: 311<br /><br />Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP (2012) <br />Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease<br /><i>J Lipids</i> <b>2012</b>: 476316<br /><br />Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Nakayama KS, Jarvik ER, Eintracht JF, Rosenthal EA, Furlong CE, Jarvik GP (2012) <br />Dietary cholesterol increases paraoxonase 1 enzyme activity<br /><i>J Lipid Res</i> <b>53</b>: 2450<br /><br />Cole TB, Beyer RP, Bammler TK, Park SS, Farin FM, Costa LG, Furlong CE (2011) <br />Repeated developmental exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1)-modulated effects on cerebellar gene expression<br /><i>Toxicol Sci</i> <b>123</b>: 155<br /><br />Costa LG, Giordano G, Furlong CE (2011) <br />Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on<br /><i>Biochemical Pharmacology</i> <b>81</b>: 337<br /><br />Furlong CE (2011) <br />Exposure to triaryl phosphates: metabolism and biomarkers of exposure<br /><i>J Biol Phys Chem</i> <b>11</b>: <br /><br />Giordano G, Cole TB, Furlong CE, Costa LG (2011) <br />Paraoxonase 2 (PON2) in the mouse central nervous system: a neuroprotective role?<br /><i>Toxicol Appl Pharmacol</i> <b>256</b>: 369<br /><br />Liyasova M, Li B, Schopfer LM, Nachon F, Masson P, Furlong CE, Lockridge O (2011) <br />Exposure to tri-o-cresyl phosphate detected in jet airplane passengers<br /><i>Toxicol Appl Pharmacol</i> <b>256</b>: 337<br /><br />Marsillach J, Richter RJ, Kim JH, Stevens RC, Maccoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE (2011) <br />Biomarkers of organophosphorus (OP) exposures in humans<br /><i>Neurotoxicology</i> <b>32</b>: 656<br /><br />Cole TB, Jansen K, Park S, Li WF, Furlong CE, Costa LG (2010) <br />The toxicity of mixtures of specific organophosphate compounds is modulated by paraoxonase 1 status<br /><i>Advances in Experimental Medicine & Biology</i> <b>660</b>: 47<br /><br />Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP (2010) <br />Human PON1, a biomarker of risk of disease and exposure<br /><i>Chemico-Biological Interactions</i> <b>187</b>: 355<br /><br />Hofmann JN, Keifer MC, De Roos AJ, Fenske RA, Furlong CE, van Belle G, Checkoway H (2010) <br />Occupational determinants of serum cholinesterase inhibition among organophosphate-exposed agricultural pesticide handlers in Washington State<br /><i>Occup Environ Med</i> <b>67</b>: 375<br /><br />Kim JH, Stevens RC, Maccoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE (2010) <br />Identification and characterization of biomarkers of organophosphorus exposures in humans<br /><i>Advances in Experimental Medicine & Biology</i> <b>660</b>: 61<br /><br />Mackenzie Ross SJ, Brewin CR, Curran HV, Furlong CE, Abraham-Smith KM, Harrison V (2010) <br />Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides<br /><i>Neurotoxicology & Teratology</i> <b>32</b>: 452<br /><br />Richter RJ, Jarvik GP, Furlong CE (2010) <br />Paraoxonase 1 status as a risk factor for disease or exposure<br /><i>Advances in Experimental Medicine & Biology</i> <b>660</b>: 29<br /><br />Schopfer LM, Furlong CE, Lockridge O (2010) <br />Development of diagnostics in the search for an explanation of aerotoxic syndrome<br /><i>Analytical Biochemistry</i> <b>404</b>: 64<br /><br />Suzuki SM, Stevens RC, Richter RJ, Cole TB, Park S, Otto TC, Cerasoli DM, Lenz DE, Furlong CE (2010) <br />Engineering human PON1 in an E. coli expression system<br /><i>Advances in Experimental Medicine & Biology</i> <b>660</b>: 37<br /><br />Ticozzi N, LeClerc AL, Keagle PJ, Glass JD, Wills AM, van Blitterswijk M, Bosco DA, Rodriguez-Leyva I, Gellera C, Ratti A, Taroni F, McKenna-Yasek D, Sapp PC, Silani V, Furlong CE, Brown RH, Jr., Landers JE (2010) <br />Paraoxonase gene mutations in amyotrophic lateral sclerosis<br /><i>Annals of Neurology</i> <b>68</b>: 102<br /><br />Hofmann JN, Keifer MC, Furlong CE, De Roos AJ, Farin FM, Fenske RA, van Belle G, Checkoway H (2009) <br />Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers<br /><i>Environmental Health Perspectives</i> <b>117</b>: 1402<br /><br />Huen K, Richter R, Furlong CE, Eskenazi B, Holland NT (2009) <br />Validation of PON1 enzyme activity assays for longitudinal studies<br /><i>Clinica Chimica Acta</i> <b>402</b>: 67<br /><br />Jansen KL, Cole TB, Park SS, Furlong CE, Costa LG (2009) <br />Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds<br /><i>Toxicol Appl Pharmacol</i> <b>236</b>: 142<br /><br />Richter RJ, Jarvik GP, Furlong CE (2009) <br />Paraoxonase 1 (PON1) status and substrate hydrolysis<br /><i>Toxicol Appl Pharmacol</i> <b>235</b>: 1<br /><br />Richter RJ, Jarvik GP, Furlong CE (2008) <br />Determination of paraoxonase 1 status without the use of toxic organophosphate substrates<br /><i>Circ Cardiovasc Genet</i> <b>1</b>: 147<br /><br />Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, Cudkowicz ME, Furlong CE, Brown RH, Jr. (2008) <br />Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS<br /><i>Neurology</i> <b>70</b>: 929<br /><br />Furlong CE (2007) <br />Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds<br /><i>J Biochem Mol Toxicol</i> <b>21</b>: 197<br /><br />Furlong CE, Holland NT, Richter RJ, Bradman A, Ho A, Eskenazi B (2006) <br />PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity<br /><i>Pharmacogenet Genomics</i> <b>16</b>: 183<br /><br />Holland NT, Furlong CE, Bastaki M, Richter R, Bradman A, Huen K, Beckman K, Eskenazi B (2006) <br />Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns<br /><i>Environmental Health Perspectives</i> <b>114</b>: 985<br /><br />Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE (2005) <br />Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism<br /><i>Pharmacogenet Genomics</i> <b>15</b>: 589<br /><br />Costa LG, Cole TB, Furlong CE (2005) <br />Paraoxonase (PON1): from toxicology to cardiovascular medicine<br /><i>Acta Biomed</i> <b>76 Suppl 2</b>: 50<br /><br />Costa LG, Cole TB, Vitalone A, Furlong CE (2005) <br />Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity<br /><i>Clinica Chimica Acta</i> <b>352</b>: 37<br /><br />Costa LG, Vitalone A, Cole TB, Furlong CE (2005) <br />Modulation of paraoxonase (PON1) activity<br /><i>Biochemical Pharmacology</i> <b>69</b>: 541<br /><br />Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG (2005) <br />Paraoxonase 1 (PON1) status and risk of insecticide exposure<br /><i>J Biochem Mol Toxicol</i> <b>19</b>: 182<br /><br />Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG (2005) <br />Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants<br /><i>Neurotoxicology</i> <b>26</b>: 651<br /><br />Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, Gortner DA, Boyko E, Schellenberg GD, Furlong CE, Jarvik GP (2005) <br />The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status<br /><i>J Lipid Res</i> <b>46</b>: 1888<br /><br />Young JG, Eskenazi B, Gladstone EA, Bradman A, Pedersen L, Johnson C, Barr DB, Furlong CE, Holland NT (2005) <br />Association between in utero organophosphate pesticide exposure and abnormal reflexes in neonates<br /><i>Neurotoxicology</i> <b>26</b>: 199<br /><br />Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, Furlong CE, Holland NT (2004) <br />Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population<br /><i>Environmental Health Perspectives</i> <b>112</b>: 1116<br /><br />Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, Furlong CE (2003) <br />Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status<br /><i>Pharmacogenetics</i> <b>13</b>: 291<br /><br />Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE (2000) <br />Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype<br /><i>Pharmacogenetics</i> <b>10</b>: 453<br /><br />Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG (2000) <br />Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1)<br /><i>Neurotoxicology</i> <b>21</b>: 91<br /><br />Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE (2000) <br />Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds<br /><i>Pharmacogenetics</i> <b>10</b>: 767<br /><br />Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE (1999) <br />The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism<br /><i>Chemico-Biological Interactions</i> <b>119-120</b>: 429<br /><br />La Du BN, Furlong CE, Reiner E (1999) <br />Recommended nomenclature system for the paraoxonases<br /><i>Chemico-Biological Interactions</i> <b>119-120</b>: 599<br /><br />Furlong CE, Li WF, Costa LG, Richter RJ, Shih DM, Lusis AJ (1998) <br />Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism<br /><i>Neurotoxicology</i> <b>19</b>: 645<br /><br />Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) <br />Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis<br /><i>Nature</i> <b>394</b>: 284<br /><br />Li WF, Matthews C, Disteche CM, Costa LG, Furlong CE (1997) <br />Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression<br /><i>Pharmacogenetics</i> <b>7</b>: 137<br /><br />Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, Furlong CE (1997) <br />Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring<br /><i>J Toxicol Environ Health</i> <b>51</b>: 35<br /><br />Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE (1996) <br />Structural organization of the human PON1 gene<br /><i>Genomics</i> <b>35</b>: 586<br /><br />Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) <br />The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin<br /><i>Nat Genet</i> <b>14</b>: 334<br /><br />Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD (1996) <br />Paraoxonase genotypes, lipoprotein lipase activity, and HDL<br /><i>Arterioscler Thromb Vasc Biol</i> <b>16</b>: 1243<br /><br />Li WF, Furlong CE, Costa LG (1995) <br />Paraoxonase protects against chlorpyrifos toxicity in mice<br /><i>Toxicology Letters</i> <b>76</b>: 219<br /><br />Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline C, Crabb JW, et al. (1993) <br />Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification<br /><i>Chemico-Biological Interactions</i> <b>87</b>: 35<br /><br />Li WF, Costa LG, Furlong CE (1993) <br />Serum paraoxonase status: a major factor in determining resistance to organophosphates<br /><i>Journal of Toxicology & Environmental Health</i> <b>40</b>: 337<br /><br />Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE (1991) <br />Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence<br /><i>Biochemistry</i> <b>30</b>: 10141<br /><br />Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE (1990) <br />Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats<br /><i>Toxicol Appl Pharmacol</i> <b>103</b>: 66<br /><br />